Bioerodible composites for endoprostheses

Patent metadata

Field	Value
Publication number	US-9446174-B2
Application number	US-201414456254-A
Country	US
Kind code	B2
Filing date	Aug 11, 2014
Priority date	Aug 28, 2013
Publication date	Sep 20, 2016
Grant date	Sep 20, 2016

Abstract

A bioerodible endoprosthesis includes a composite including a matrix comprising a bioerodible magnesium alloy and a plurality of ceramic nanoparticles within the matrix. The bioerodible magnesium alloy has a microstructure including equiaxed Mg-rich solid solution-phase grains having an average grain diameter of less than or equal to 5 microns. The microstructure can be produced by one or more equal-channel high-strain processes.

First claim

What is claimed is:

1. A bioerodible endoprosthesis comprising:
a composite comprising a matrix comprising a bioerodible magnesium alloy and a plurality of ceramic nanoparticles within the matrix, the bioerodible magnesium alloy comprising magnesium and one or more additional alloying elements, the bioerodible magnesium alloy comprising equiaxed Mg-rich solid solution phase grains;
wherein the equiaxed Mg-rich solid solution phase grains have an average grain diameter of less than or equal to 20 microns and the ceramic nanoparticles have an average longest dimension of between 0.1 nanometers and 1 micron.

2. The endoprosthesis of claim 1 , wherein the ceramic nanoparticles are primarily centered upon the grain boundaries and do not extend into a Mg-rich solid solution phase grain interior by more than 1 micron from the grain boundary when viewed at 200-500X magnification on a metallography plane.

3. The endoprosthesis of claim 1 , wherein the equiaxed Mg-rich solid solution phase grains have an average grain diameter of less than or equal to 1 micron and the ceramic nanoparticles have an average longest dimension of between 0.5 nanometer and 200 nanometers.

4. The endoprosthesis of claim 1 , wherein less than 50% of the equiaxed Mg-rich solid solution-phase grains have twin bands.

5. The endoprosthesis of claim 4 , wherein less than 15% of the equiaxed Mg-rich solid solution-phase grains have twin bands.

6. The endoprosthesis of claim 1 , wherein the bioerodible magnesium alloy includes beta-phase precipitates.

7. The endoprosthesis of claim 1 , wherein the ceramic nanoparticles are insoluble in the bioerodible magnesium alloy.

8. The endoprosthesis of claim 1 , wherein the ceramic nanoparticles comprise a ceramic material selected from the group consisting of TiC, Si 3 N 4 , AlN, Al 2 O 3 , CeO 2 , Boron Nitride, B 4 C, Y 2 O 3 , and combinations thereof.

9. The endoprosthesis of claim 1 , wherein the alloy has an elastic modulus of between 39 GPa and 200 GPa, a 0.2% offset yield strength of between 150 MPa and 600 MPa, an ultimate tensile strength of between 250 MPa and 600 MPa, and a tensile reduction in area of at least 30%.

10. The endoprosthesis of claim 1 , wherein the bioerodible magnesium alloy comprises aluminum.

11. The endoprosthesis of claim 1 , wherein the bioerodible magnesium alloy comprises zinc, calcium, manganese, neodymium, tin, yttrium, cerium, lanthanum, gadolinium, or a combination thereof.

12. The endoprosthesis of claim 1 , wherein the bioerodible magnesium alloy comprises between 3 and 9 weight percent aluminum, between 0.1 and 3.0 weight percent zinc, up to 0.3 weight percent manganese, and between 0.6 and 1.5 weight percent neodymium, and balance magnesium.

13. The endoprosthesis of claim 1 , wherein the endoprosthesis is a stent comprising a plurality of struts, wherein the struts have a width to thickness ratio of less than 1.2.

14. The endoprosthesis of claim 1 , wherein the endoprosthesis has a surface finish having an R a surface roughness of less than 0.2 microns.

15. The endoprosthesis of claim 1 , wherein the fully manufactured non-sterile or sterile finished product bare bioerodible magnesium alloy-ceramic composite endoprothesis has a mass loss of less than 10% after 28 days of continuous immersion in non-flowing, agitated Simulated Body Fluid at 37° C., where the Simulated Body Fluid has a volume of at least 10 times an initial volume of the stent.

16. A bioerodible endoprosthesis comprising:
a composite comprising a matrix comprising a bioerodible magnesium alloy and a plurality of ceramic nanoparticles within the matrix, the bioerodible magnesium alloy comprising magnesium and one or more additional alloying elements, the bioerodible magnesium alloy comprising equiaxed Mg-rich solid solution phase grains:
wherein less than 50% of the equiaxed Mg-rich solid solution-phase grains have twin bands.

17. A bioerodible endoprosthesis comprising:
a composite comprising a matrix comprising a bioerodible magnesium alloy and a plurality of ceramic nanoparticles within the matrix, the bioerodible magnesium alloy comprising magnesium and one or more additional alloying elements, the bioerodible magnesium alloy comprising equiaxed Mg-rich solid solution phase grains;
wherein the bioerodible magnesium alloy includes beta-phase precipitates.

Assignees

• Boston Scient Scimed Inc

Inventors

• Weber Jan
• Edick Jacob Drew

Classifications

• B21C23/001

  to improve the material properties, e.g. lateral extrusion · CPC title

• C22F1/06

  of magnesium or alloys based thereon · CPC title

• A61L2400/12

  Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces · CPC title

• A61F2/82

  Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07) · CPC title

• A61L31/124

  of other specific inorganic materials not covered by A61L31/122 or A61L31/123 · CPC title